Hengrui Medicine (01276.HK): Injection SHR-1826, Adcetris monoclonal antibody injection, Bavencio monoclonal antibody injection received clinical trial approval notice.

Zhixin Finance APP News, Hengrui Medicine (01276.HK) announced that recently, the company's subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Pharmaceutical Co., Ltd., have received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the injection SHR-1826, Atezolizumab Injection, and Bevacizumab Injection. Clinical trials will be carried out soon.